REG - Ergomed plc - Total Voting Rights & Block Listing Return
RNS Number : 5881RErgomed plc01 July 2020PRESS RELEASE
Total Voting Rights and Block Listing Return
Total Voting Rights
Guildford, UK - 1 July 2020: In accordance with the Financial Conduct Authority's Disclosure Guidance and Transparency Rules (DTRs), Ergomed plc (the "Company") announces the following information.
The Company's issued share capital as at 30 June 2020 consisted of 48,215,791 ordinary shares of 1p each, none of which were held in treasury. Each ordinary share in the capital of the Company carries one voting right.
The above figure may be used by shareholders as the denominator for the calculations by which they will determine if they are required to notify their interest in, or a change to their interest in, the Company, under the DTRs.
Block Listing Six Monthly Return
Name of applicant:
Ergomed plc
Name of scheme:
Ergomed plc Long Term Incentive Plan
Period of return:
From:
1 January 2020
To:
30 June 2020
Balance of unallotted securities under scheme(s) from previous return:
2,133,959
Plus: The amount by which the block scheme(s) has been increased since the date of the last return (if any increase has been applied for):
nil
Less: Number of securities issued/allotted under scheme(s) during period (see LR3.5.7G):
214,502
Equals: Balance under scheme(s) not yet issued/allotted at end of period:
1,919,457
Number and class of securities originally admitted and the date of admission
1,800,000 ordinary shares of 1p each - 2 July 2018
1,500,000 ordinary shares of 1p each - 31 December 2019
Total number of securities in issue at the end of the period
48,215,791 ordinary shares of 1p each
Name of contact:
Nick Roberts - Head of Group Reporting
Telephone number of contact:
+44 (0) 1483 503 205
ENDS
Enquiries:
Ergomed plc
Tel: +44 (0) 1483 402 975
Miroslav Reljanović (Executive Chairman)
Richard Barfield (Chief Financial Officer)
Numis Securities Limited
Tel: +44 (0) 20 7260 1000
Freddie Barnfield / Huw Jeremy (Nominated Adviser)
James Black (Broker)
Consilium Strategic Communications - for UK enquiries
Tel: +44 (0) 20 3709 5700
Chris Gardner / Sue Stuart
ergomed@consilium-comms.com
Matthew Neal / Olivia Manser
About Ergomed plc
Ergomed provides specialist services to the pharmaceutical industry spanning all phases of clinical development, post-approval pharmacovigilance and medical information. Ergomed's fast-growing, profitable services business includes an industry leading suite of specialist pharmacovigilance (PV) solutions, integrated under the PrimeVigilance brand, a full range of high-quality contract research and trial management services under the Ergomed brand (CRO), and an internationally recognised specialist expertise in orphan drug development, under PSR. For further information, visit: http://ergomedplc.com.
This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact rns@lseg.com or visit www.rns.com.ENDTVRFLFIERRIIVII
Recent news on Ergomed
See all newsREG - Ergomed plc - Cancellation of admission to trading of shares
AnnouncementREG - AIM Ergomed plc - Cancellation - Ergomed plc
AnnouncementREG - Takeover Panel - Disclosure Table
AnnouncementREG-Millennium Partners, L.P. Form 8.3 - Ergomed plc
AnnouncementREG - BlackRock Group Ergomed plc - Form 8.3 - Ergomed plc
Announcement